Le Lézard
Classified in: Health
Subjects: RCL, PSF

Advisory - Multiple unauthorized health products seized from Isabella Beauty Salon in the Greater Toronto Area


OTTAWA, Sept. 22, 2017 /CNW/ -

Issue
Health Canada is advising Canadians that it has seized 10 unauthorized health products that may pose serious risks to health. The products were seized from Isabella Beauty Salon, at 86 Finch Ave E., North York, ON.

The products seized include injectable and topical drugs that are packaged and labelled in Japanese, Korean or Chinese. As a result, information about ingredients, usage, dosage and side effects may not be understood by all users. None of the products are authorized for sale in Canada, which means they have not been assessed for safety, effectiveness or quality.

Who is affected

Affected product

What consumers should do

What Health Canada is doing
Health Canada seized the unauthorized products from Isabella Beauty Salon, at 86 Finch Ave E., North York, ON. Health Canada is working with the Canada Border Services Agency to help prevent further importation of these products. Should additional retailers or distributors be identified, Health Canada will take appropriate action and inform Canadians as necessary.

Background

Aminogen-X is a product containing amino acids, vitamins and minerals. The target population and indication for use is not clearly identified on the product label. Potential risks associated with injecting this unauthorized product may include infection at the site of injection and sepsis (blood poisoning). Patients with liver or kidney impairment may experience complications, including increased ammonia levels in the blood, fluid and electrolyte imbalance, impaired consciousness and even coma.

Liporase is a product labelled to contain hyaluronidase. Products containing hyaluronidase are used in ophthalmic surgery and are reportedly also used experimentally in some countries to manage complications from cosmetic procedures. The potential risks associated with injecting a hyaluronidase product can include redness of the skin, irregular heartbeat, confusion and blurred vision. Additionally, serious side effects can occur when certain medicines are used together with hyaluronidase.

Sodium Chloride 0.9% is a fluid and electrolyte replacement product. Potential risks associated with injecting this unauthorized product may include infection at the site of injection or sepsis. Patients with heart failure, kidney failure or liver failure who receive this product may be at increased risk for fluid and electrolyte imbalances.

J-CAIN is labelled to contain lidocaine. Lidocaine cream is considered safe when used in small amounts and low concentrations over small areas of the body. However, this cream is labelled to contain a 15.6% concentration. Health Canada has not done a safety review of creams containing lidocaine at a high concentration. When 15.6% lidocaine cream is applied on the body, a significant amount of lidocaine may be absorbed into the bloodstream, which may cause the buildup of toxic levels of lidocaine in the body. The toxicity of lidocaine can be local or systemic. Symptoms of local toxicity may include redness, itching, burning and swelling in the application area. Systemic toxicity most often affects the central nervous system or the cardiovascular system. Severe symptoms of systemic toxicity may include irregular heartbeat, difficulty breathing, seizure, coma and death.

For more information

Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.

To learn more about natural health products and other self-care products, visit Canada.ca/selfcare-products.

Également disponible en français

 

SOURCE Health Canada


These press releases may also interest you

at 08:07
Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, has released a comprehensive contract research organization (CRO) offering tailor-made for sponsors looking to bring diagnostic products...

at 08:05
Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today the enrollment of the first patient in a pilot study collecting patient-generated health data (PGHD) during proton radiotherapy for lung cancer in...

at 08:05
Roivant and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for...

at 08:05
Revvity, Inc. will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV. Senior Vice President and Chief Financial Officer Max Krakowiak will provide an update on the Company and its...

at 08:05
Freedom Biosciences, Inc. ("Freedom Bio" or the "Company"), a clinical-stage biotechnology platform focused on developing next-generation neuropsychiatric therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has notified the...

at 08:05
Microbion Corporation today announced that the company won the Advanced Wound Care Summit's Innovation Showcase award. The Innovation Showcase was designed to give presenters, who were picked by a selection committee, an opportunity to demonstrate...



News published on and distributed by: